Gut Microbiome and Hyperlipidemia

Hyperlipidemia is one of the most common metabolic disorders of modern lifestyles. Most people encounter it during routine blood tests as “high cholesterol” or “elevated triglycerides.” Although it often causes no symptoms, hyperlipidemia is a fundamental risk factor for cardiovascular diseases such as atherosclerosis, heart attacks, and strokes.

However, how many people know that the gut microbiome, the collection of microorganisms living in our intestines, plays a decisive role in regulating the lipid profile? Through which mechanisms do gut bacteria affect blood cholesterol and triglyceride levels? And most importantly, what can we do to leverage this knowledge for prevention or treatment?

In recent years, science has demonstrated that metabolic diseases are not simply a matter of diet or genetic predisposition, but the result of a complex system, in which the microbiome plays a central role.

How the Microbiome Affects Lipids: Biological Mechanisms

The gut is not just a digestive organ but a dynamic metabolic and immunological hub. It operates as an ecosystem, hosting trillions of microorganisms and constantly interacting with our cells and the nutrients we ingest.

An essential discovery of the last decade is that the microbiome is not neutral. On the contrary, it actively participates in critical metabolic functions, including the regulation of glucose and free fatty acids, as well as cholesterol and triglyceride metabolism. Some key mechanisms through which the gut microbiome influences the lipid profile are the following:

1. Production of short-chain fatty acids (SCFAs): During the breakdown of dietary fibers, certain gut bacteria produce short-chain fatty acids (SCFAs). A microbiome lacking in SCFA-producing bacteria (such as Faecalibacterium prausnitzii, Roseburia spp.) is associated with disturbances in the lipid profile, as SCFAs are metabolic products capable of:

Enhancing hepatic insulin sensitivity
Reducing cholesterol synthesis in the liver
Regulating inflammation at the metabolic level

2. Bile acid degradation: The synthesis and ratio of bile acids are closely linked to LDL and HDL cholesterol levels. Gut microbiota are involved in converting primary bile acids into secondary ones, influencing:

Fat absorption
Intestinal motility
Hepatic cholesterol recycling

3. Regulation of intestinal permeability (leaky gut): A dysregulated microbiome can lead to increased permeability of the intestinal barrier, which in turn results in:

Endotoxin (LPS) infiltration into circulation
Activation of systemic inflammation
Induction of hepatic VLDL and triglyceride production

4. Endogenous fat synthesis and storage: The microbiome can affect genetic pathways involved in adipocyte fat storage, thereby indirectly influencing the lipid profile. Notably, two individuals with the same diet and lifestyle may have completely different lipid levels if their microbial populations differ. This also explains why many patients with a “proper” diet still have high LDL, or why some respond better to specific lipid-lowering drugs or diets.

Functional Laboratory Investigation of Hyperlipidemia: Focusing on the “Why”

In standard clinical practice, hyperlipidemia is often treated as a number, leading, for example, to the prescription of statins when LDL is elevated, or to dietary modifications when triglycerides are high. This approach is helpful for risk management but often overlooks the deeper causes of the condition.

Functional medicine seeks to do precisely that: identify and understand the underlying substrate of each pathology by combining data from various body systems. In the functional investigation of hyperlipidemia, it is essential to collect information about the microbial ecology and health of the gut, the individual's metabolic state and balance, and the possible activation of inflammatory mechanisms, posing questions such as:

Is there dysbiosis (imbalance) in the gut microbiome affecting lipid synthesis?
Could there be intestinal permeability aggravating the gut-liver axis?
Is there low-grade inflammation enhancing hepatic lipoprotein production?

To approach these questions in the context of hyperlipidemia, some of the most powerful diagnostic tools are:

EnteroScan®: A modern molecular analysis of the gut microbiome, assessing microbial biodiversity, including the ratio of beneficial and potentially pathogenic bacteria. It also evaluates SCFA production capacity and detects the presence of inflammatory markers or indicators of increased intestinal permeability (leaky gut). For example, individuals with hyperlipidemia often show reduced populations of butyrate-producing bacteria and an elevated Firmicutes/Bacteroidetes ratio, which may be linked to metabolic syndrome.
Homocysteine and Apolipoprotein B (ApoB): Markers of metabolic vulnerability.
Chronic Inflammation Panel (ImmuneScan®): Includes low-grade inflammation markers and other immune molecules associated with lipogenic activity and cardiovascular risk prevention.

Based on the above, a personalized therapeutic plan can be developed, emphasizing a diet tailored to the microbial findings, supportive supplementation with prebiotics, probiotics, phytochemicals, and enzymatic compounds, and lifestyle interventions, especially stress management and sleep quality.

Practical Advice: Supporting the Microbiome and the Lipid Profile

Enhancing the gut microbiome's health doesn’t require radical changes; instead, it requires targeted, consistent choices with strong scientific backing. Modifying the microbial ecosystem can improve cholesterol and triglyceride levels and overall cardiometabolic health. Below are the main pillars of a practical, daily strategy:

1. Nutrition: Dietary fibers are the “food” for the most beneficial gut bacteria, which produce short-chain fatty acids (SCFAs). Continuous exposure of the microbiome to a variety of fibers increases its biodiversity, something that is associated with lower LDL levels and protection against inflammation. On the other hand, overconsumption of saturated fats promotes microbial compositions that increase endotoxin (LPS) production, leading to increased intestinal permeability and negatively affecting hepatic lipid metabolism. Instead, favor healthy fats such as monounsaturated and omega-3 fatty acids. To optimally care for the microbiome while simultaneously supporting the lipid profile, it is recommended to consume regularly the following:

Sources of prebiotics and natural enzymes: e.g., artichokes, leeks, asparagus, lentils, chickpeas, black-eyed peas, green bananas, and other tropical fruits (papaya, pineapple)
Sources of inulin: onion, garlic, leek
Probiotics: fermented foods (such as kefir, yogurt, sauerkraut, kombucha)
Sources of monounsaturated fats: olive oil, avocado, olives
Sources of omega-3 fatty acids: mainly oily fish such as sardines, mackerel, salmon, as well as walnuts and flaxseeds

2. Stress Management and Sleep Quality: The gut microbiome is sensitive to stress and circadian rhythm disruptions. Stress-related strain on the microbiome may, in turn, burden metabolism and the lipid profile. Studies have shown that increased stress alters the ratio of friendly to pathogenic bacteria and is associated with higher triglyceride levels. You can significantly support your health by aiming for:

At least 6-7 hours of nighttime sleep, at regular hours
Stress management through calming techniques like diaphragmatic breathing, light walking, and meditation
Limiting caffeine and blue light exposure during the evening

3. Re-evaluating the Use of Antibiotics: Long-term or unnecessary antibiotic use leads to deep dysregulation of the microbiome. Through the mechanisms described earlier, one possible long-term consequence is the development of hyperlipidemia. Microbial restoration after antibiotic treatment is a crucial factor necessary for maintaining a healthy balance in the gut ecosystem.

Conclusions and Next Steps: The Microbiome at the Core of Prevention

Hyperlipidemia, therefore, is not addressed solely with medication or by avoiding fats. By leveraging Functional Medicine's expertise, we seek and target a deeper potential cause that is often overlooked. The gut microbiome, as a critical regulator of metabolism, inflammation, and liver function, is now emerging as a central tool in the prevention and management of dyslipidemias. Investigating its health status can lead to the development and implementation of personalized intervention strategies that support proper microbial balance and optimize the lipid profile.

What you can do today:

Discover what is really happening in your body with an EnteroScan®, a specialized functional microbiome test that reveals valuable insights about your gastrointestinal and metabolic balance.
See how Functional Medicine can help you in practice, by identifying root causes instead of just masking symptoms.
Subscribe to our newsletter to be the first to receive updates on new preventive tests, wellness articles, and practical advice from Diagnostiki

References

Wang Z, Koonen D, Hofker M, Fu J. Gut microbiome and lipid metabolism: from associations to mechanisms. Curr Opin Lipidol. 2016;27(3):216-224.
Münte E, Hartmann P. The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases. Biomolecules. 2025 Mar 22;15(4):469.
Xu, Q., Wang, W., Li, Y. et al. The oral-gut microbiota axis: a link in cardiometabolic diseases. npj Biofilms Microbiomes 11, 11 (2025).

At Diagnostiki Athinon, we treat prevention with the seriousness it deserves. This is where science meets personalized care.